Ultimovacs
About:
Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer.
Website: https://ultimovacs.com/
Twitter/X: ultimovacs
Description:
Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer. The lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase.UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs that require an ongoing T cell response for their mode of action. Ultimovacs is performing a broad clinical development program with clinical trials in Europe and the USA. The company and its proprietary technology are based on pre-clinical and clinical research on immunotherapies conducted at the Oslo University Hospital. The company is a limited public liability company listed on the Oslo Stock Exchange in Norway.
270M NOK
$1M to $10M
Oslo, Oslo, Norway
2011-01-01
ir(AT)ultimovacs.com
Øyvind K. Arnesen
11-50
2021-10-26
Public
© 2025 bioDAO.ai